33. (New) The pharmaceutical composition of claim 32, wherein said gene codes for a soluble costimulatory factor that is able to dimerize.

34. (New) The pharmaceutical composition of claim 33, wherein a monomer of said costimulatory factor is B7.

35. (New) The pharmaceutical composition of claim 34, wherein said costimulatory factor comprises a protein or peptide linker sequence that joins extracellular domains of said costimulatory factor.

36. (New) The pharmaceutical composition of claim 35, wherein said linker sequence is comprised of an immunoglobulin Fc region.

37. (New) The pharmaceutical composition of claim 36, wherein said linker sequence is comprised of an IgG Fc region.

38. (New) The pharmaceutical composition of claim 37, wherein said gene is contained in a viral vector.

39. (New) The pharmaceutical composition of claim 38, wherein said viral vector is a herpes virus vector.

40. (New) The pharmaceutical composition of claim 39, wherein said viral vector is an amplicon vector.

41. (New) The method of claim 16, wherein at least one of said monomers is B7.

42. (New) The method of claim 41, wherein said vector is a viral vector.

43. (New) The method of claim 42, wherein said viral vector is a herpes virus vector.

44. (New) The method of claim 43, wherein said viral vector is an amplicon vector.

45. (New) The method according to claim 42, wherein said administrating comprises introducing said composition directly into said tumor or a local area of said tumor.

46. (New) The method according to claim 45, wherein said administering comprises directly injecting said nucleotide sequence or directly injecting said nucleotide sequence conjugated to a liposome carrier.

47. (New) The method according to claim 46, wherein said viral vector is an amplicon vector.